New diabetes shot every two weeks could rival weekly drug

NCT ID NCT06257966

Ongoing Disease control Sponsor: Beijing Dongfang Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial compares two doses of an experimental drug called JY09 against the approved drug dulaglutide in 600 adults with type 2 diabetes not well controlled by metformin alone. Participants receive either JY09 every two weeks or dulaglutide once a week for 54 weeks. The main goal is to see how well each treatment lowers blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JY09 (exendin-4 Fc fusion protein injection)
What this could lead to: If it works, JY09 could offer a convenient biweekly injection option to help control blood sugar in people with type 2 diabetes.
What could go wrong: This is a phase 3 trial, but JY09 is still experimental. It may not prove better or safer than existing weekly dulaglutide, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE2 DIABETES MELLITUS

Contacts and locations

Locations

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.